Dermatology

In this interview, Chovatiya spoke with the editorial team about the global prevalence findings on patients with seborrheic dermatitis and their implications.

Atopic dermatitis increases stress, depression, anxiety, and suicidal ideation, affecting patients' mental health, a recent study found.

Study finds 70% of atopic dermatitis patients using dupilumab continued for up to 5 years, but 23.8% discontinued primarily due to adverse events or ineffectiveness.

In this analysis, investigators highlighted the perceptions of individuals with HS and atopic dermatitis and assessed higher rates of stigmatization.

These data point to differences between genders such as time to initiation of treatment, treatment choice, response to medication, adverse events, and adherence.

New study highlights racial disparities in psoriasis management, revealing non-Hispanic Black patients are twice as likely to receive a skin biopsy compared to White counterparts.

These findings were the result of an active-comparator study, highlighting the benefits of betamethasone versus tacrolimus among patients with eczema.

These data from the United Arab Emirates provide insight into the comorbidities, epidemiology, patterns of treatment, and use of healthcare resources of alopecia areata patients.

Brett King, MD, PhD, discusses the LEVEL UP trial and how it represents the field of dermatology's desire to advance care and advocate for new standards of care.

In this Month in Review, the editorial team highlights major news covered in the field of dermatology, including FDA approvals, interviews, and new findings on drugs in the pipeline.

In this episode of Crisis Point, 3 experts in dermatology discuss ways in which those in the field are working to improve visibility of diverse skin types within dermatology education.

These data indicate the need for future analyses of possible chronic urticaria activity biomarkers, as well as other elements of patient response to omalizumab treatment.

These findings support delgocitinib’s clinical benefit as a possible medication option for individuals with moderate to severe chronic hand eczema.

Brett King, MD, PhD, discusses how the deuruxolitinib approval impacts the treatment landscape of alopecia areata.

Adults with severe alopecia were shown to have statistically significant efficacy across 2 phase 3 clinical studies highlighted in this announcement.

Following this pooled analysis, there may be a need for additional research conducted to identify other targets for achievement of optimal repigmentation.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

These findings suggest that those with atopic dermatitis exacerbations may need to limit their oral corticosteroid duration for the purposes of limiting AEs.

In this Q&A interview, Stein Gold discusses new phase 3 findings regarding ruxolitinib cream 1.5% for patients 2 to 11 years old with atopic dermatitis.

A phase 2 trial showed cendakimab, an IL-13 inhibitor, reduced Eczema Area and Severity Index scores in moderate to severe atopic dermatitis patients.

In this interview, Rosmarin discussed the results of a new post-hoc analysis of the TRuE-V1 and TRuE-V2 studies on treating younger vitiligo patients with ruxolitinib cream.

A study found omega-3 supplements and a Mediterranean diet improved acne severity and quality of life in patients without prescription meds.

In this analysis, investigators highlighted the results of treating psoriasis with deucravacitinib in the phase 3 POETYK PSO-1 and PSO-2 trials.

These data suggest the necessity of additional research to explore seborrheic dermatitis as well as its variations among many diverse groups and populations.

In this post-hoc analysis, investigators highlighted benefits of deucravacitinib among those with psoriasis compared to benefits of apremilast.